WALTHAM, MA--(Marketwire - October 22, 2008) - EyeGate Pharma, a specialty pharmaceutical company using iontophoresis technology to safely and non-invasively deliver therapeutics to treat serious ocular diseases, today announced the board appointments of Mr. Paul G. Chaney as Chairman of the Board, and Morton Goldberg, M.D., as Director. Mr. Chaney is currently a consultant at Eyetech, which recently spun out of (OSI) Eyetech. Mr. Chaney was Executive Vice President of OSI Pharmaceuticals and President of (OSI) Eyetech, OSI's eye care subsidiary. Dr. Morton F. Goldberg is a Joseph E. Green Professor of Ophthalmology at the Wilmer Eye Institute, Johns Hopkins University School of Medicine(1).
